EUR 0.36
(0.42%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 12.34 Million EUR | 8.65% |
2022 | 10.68 Million EUR | 2.11% |
2021 | 10.46 Million EUR | 4.75% |
2020 | 9.98 Million EUR | 652.49% |
2019 | -1.8 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 2.71 Million EUR | 0.0% |
2024 Q1 | 2.71 Million EUR | -25.41% |
2023 Q4 | 3.63 Million EUR | 0.0% |
2023 FY | 11.6 Million EUR | 8.65% |
2023 Q3 | 3.63 Million EUR | 43.28% |
2023 Q2 | 2.53 Million EUR | 0.0% |
2023 Q1 | 2.53 Million EUR | 4.4% |
2022 FY | 10.68 Million EUR | 2.11% |
2022 Q4 | 2.43 Million EUR | 0.0% |
2021 FY | 10.46 Million EUR | 4.75% |
2020 FY | 9.98 Million EUR | 652.49% |
2019 FY | -1.8 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Nicox S.A. | -11.5 Million EUR | 207.311% |
European Medical Solutions | 13.64 Million EUR | 9.548% |
PHAXIAM Therapeutics S.A. | 24.98 Million EUR | 50.596% |